Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT-001 with pembrolizumab in advanced solid tumors
NCT04725331Phase 2Terminated
- Sponsor
- Transgene SA
- Start
- Feb 2021
- Primary completion
- Oct 2025
- Modality
- Oncolytic Viruses, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of BT-001 in soft tissue sarcoma (STS), Merkel cell carcinoma (MCC), melanoma, triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), sponsored by Transgene SA. Started Feb 2021; status: terminated.
02
Drugs
BT-001
03
Conditions
soft tissue sarcoma (STS)Merkel cell carcinoma (MCC)melanomatriple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04725331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04725331.